Respicardia Revenue and Competitors
Estimated Revenue & Valuation
- Respicardia's estimated annual revenue is currently $24.1M per year.
- Respicardia received $58.5M in venture funding in December 2017.
- Respicardia's estimated revenue per employee is $251,000
- Respicardia's total funding is $160.2M.
- Respicardia has 96 Employees.
- Respicardia grew their employee count by 10% last year.
What Is Respicardia?
Founded in 2006 and headquartered near Minneapolis, Minnesota, Respicardia® is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remed® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular healthone breath at a time.keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals
Number of Employees
Employee Growth %
Medtronic, Respicardia Inc., Inspire Medical Systems, Siesta Medical Inc., LivaNova PLC, and LinguaFlex. Key Benefits For Stakeholders.
Sleep Apnea Implants Market Key Players- Inspire Medical Systems, Respicardia, Inc., Medtronic Plc, LinguaFlex LLC, Siesta Medical, Inc.
At Versant, he invested in a number of Minnesota companies like Metavention, Respicardia and Monteris Medical. Vensana, however, isn't ...
A new study of Respicardia's Remede central sleep apnea (CSA) implant showed long-term safety and sustained improvement in sleep metrics ...
“We're honored to continue supporting Respicardia in bringing their therapy to market,” said Tony Gonzalez, president of Integer's Cardiac ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|2017-12-19||$58.5M||Undisclosed||ZOLL Medical Corporation||Article|